Summary

Your AGTR1 A1166C result determines how responsive your angiotensin II receptor is — CC carriers have increased receptor activity that amplifies the final step of the blood pressure cascade, making them particularly salt-sensitive and particularly responsive to ARB medications (losartan, valsartan) if blood pressure intervention is ever needed.

Genotype spectrum

AA (reference)

Your blood pressure cascade operates at standard sensitivity. The angiotensin II signal is received and processed normally.

AC (A1166C heterozygous)

You're in the zone where lifestyle measures have clear protective value. Your mildly increased receptor sensitivity means that dietary and exercise interventions produce measurable benefits — you'll see a genuine return on cardiovascular health investment.

CC (C/C homozygous)

ARBs are specifically designed to block this receptor, and your genotype predicts enhanced response. If medication is ever needed, you have clear pharmacogenomic guidance.

Practical takeaway

For CC Carriers (Highest Receptor Activity)

Sodium management:
• Target <1,500 mg/day. Your amplified receptor sensitivity means the sodium-retention arm of angiotensin II signalling runs harder. Sodium restriction reduces the substrate for this retention.
• Same practical strategies as AGT GG carriers: processed food awareness, home cooking, label reading. See agt_angiotensinogen entry for detailed sodium reduction strategies.
• If you carry BOTH AGT GG and AGTR1 CC: sodium restriction is doubly targeted — you're addressing amplified production AND amplified reception. This is one of the clearest precision nutrition scenarios in cardiovascular genetics.

Potassium and magnesium:
• Potassium: 3,500-4,700 mg/day from food sources. Directly counteracts aldosterone-driven sodium retention.
• Magnesium: 400-420 mg/day (men), 310-320 mg/day (women). Supports vascular relaxation and is a natural calcium channel modulator.
• Food first: supplements only if dietary intake is consistently insufficient.

Exercise:
• Regular aerobic exercise (150+ minutes/week moderate, or 75+ minutes vigorous). This directly reduces angiotensin II signalling and improves vascular compliance.
• Resistance training is not contraindicated but should be paired with adequate aerobic work. Heavy isometric holds cause acute BP spikes — include dynamic movement and proper breathing technique.

Blood pressure monitoring:
• Home BP monitor. Weekly readings at the same time, seated, after 5 minutes rest.
• Log your readings. Look for trends, not individual numbers.
• Target: <130/80 mmHg consistently. Ideal: <120/80 mmHg.

Pharmacogenomic note:
• If medication is ever needed, ARBs (losartan, valsartan, candesartan) are specifically well-suited to your genotype. These drugs block the receptor that your variant has amplified. This is genuine pharmacogenomic guidance — mention your AGTR1 genotype to your prescribing GP.
• ARBs vs. ACE inhibitors: both target the RAS, but ARBs block at the receptor (your amplified component), while ACE inhibitors block upstream conversion. If you carry BOTH ACE DD and AGTR1 CC, discuss with your GP which target point makes more sense — or combination therapy.

What "wo

Evidence detail

What This Gene Does

AGTR1 encodes the angiotensin II type 1 receptor — the final target of the renin-angiotensin system. This receptor sits on the surface of vascular smooth muscle cells, adrenal cells, and kidney cells. When angiotensin II binds to it, blood vessels constrict, aldosterone is released (causing sodium and water retention), and the sympathetic nervous system activates. It's the receptor where the blood pressure signal is actually received and executed.

The A1166C variant (rs5186) in the 3' untranslated region affects receptor expression levels. The C allele is associated with increased receptor activity — not by changing the receptor's structure, but by altering mRNA stability, leading to more receptors on cell surfaces. More receptors means the same amount of angiotensin II produces a larger downstream effect.

Mechanism

AGTR1 is the endpoint of the renin-angiotensin cascade:

1. AGT (liver) → angiotensinogen
2. Renin (kidneys) → angiotensin I
3. ACE → angiotensin II
4. Angiotensin II binds AGTR1 → vasoconstriction + aldosterone release + sodium retention + sympathetic activation + vascular remodelling

The A1166C variant sits in the 3' untranslated region of the AGTR1 mRNA. It disrupts a binding site for microRNA-155 (miR-155). Normally, miR-155 binds here and promotes mRNA degradation — a natural brake on receptor production. The C allele weakens this brake:
• A allele: miR-155 binds effectively → normal AGTR1 mRNA turnover → standard receptor density
• C allele: miR-155 binding disrupted → less mRNA degradation → more AGTR1 protein → more receptors on cell surfaces → amplified angiotensin II response

This is a gain-of-function variant at the receptor level. The same concentration of angiotensin II produces a larger effect in C allele carriers because there are more receptors to bind. This amplifies:
• Vasoconstriction: More receptors on vascular smooth muscle → tighter blood vessels
• Aldosterone release: More receptors on adrenal cells → more sodium and water retention
• Vascular remodelling: Chronic receptor overstimulation promotes smooth muscle hypertrophy → stiffer arteries over time

Why ARBs work so well for this genotype:

ARBs (losartan, valsartan, candesartan) are competitive antagonists at the AGTR1 receptor. They sit in the binding site and block angiotensin II from activating the receptor. If you have more receptors (CC genotype), you have more targets for the drug to block — and blocking them has a proportionally larger effect because you were starting from a higher baseline of receptor-mediated signalling.

AGTR1 Receptor

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (8)